Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma

We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bcr-Abl, when administered for 8 days in combi...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Sathornsumetee, Sith, Rich, Jeremy N., Quinn, Jennifer A., Lagattuta, Theodore F., Egorin, Merrill J., Gururangan, Sridharan, McLendon, Roger, Herndon, James E., Friedman, Allan H., Salvado, August J., Friedman, Henry S.
格式: Artigo
語言:Inglês
出版: Duke University Press 2008
主題:
Clinical Investigations
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC2563055/
https://ncbi.nlm.nih.gov/pubmed/18359865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2008-003
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍